Rxrx stock forecast.
Analyst projections state that RXRX is forecast to be at a low of $9.00 and a high of $35.00. In order for the stock price to hit the forecast high, the stock would need to plunge -532.91% from its current level, while the stock would need to crash -62.75% from its current level to reach the projected low.
One thing we could say about the analysts on Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - they aren't optimistic, having just made a major negative revision to their near-term (statutory ...Dec 1, 2023 · Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More. According to our current RXRX stock forecast, the value of Recursion Pharmaceuticals, Inc. shares will drop by -9.72% and reach $ 6.59 per share by December 5, 2023. …Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...
Recursion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. RXRX updated stock price target summary.
RXRX has a market cap of $1.73bn and a cash balance of $454mn. Research and development expenses were $40.8 million for the third quarter of 2022, while general and administrative expenses were ...Find the latest news headlines from Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.
Scores. RXRX has an Altman Z-Score of 1.67 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.Nasdaq.com will report pre-market and after hours trades. Pre-Market trade data will be posted from 4:15 a.m. ET to 7:30 a.m. ET of the following day. After Hours trades will be posted from 4:15 p ...Jul 13, 2023 · Recursion Pharmaceuticals, Inc. (RXRX) : Free Stock Analysis Report. Omega Therapeutics, Inc. (OMGA) : Free Stock Analysis Report ... according to the forecast. 7h ago. Zacks. 2 Stocks to Buy from ... Follow your favorite stocks CREATE FREE ACCOUNT Over the next 10 years, AI could increase productivity by 1.5 percent per year. And that could increase S&P500 profits by 30 percent or more over ...Gas prices are at a record high, and experts are forecasting that prices could go higher this summer — perhaps $5 or even over $6 a gallon. By clicking "TRY IT", I agree to receive newsletters and promotions from Money and its partners. I a...
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.
Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX.
See Recursion Pharmaceuticals, Inc. (RXRX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.RXRX has an Altman Z-Score of 1.55 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy. Detailed statistics for Recursion Pharmaceuticals, Inc. (RXRX) stock, including valuation metrics, financial numbers, share information and more.Recursion Pharmaceuticals Stock Chart and Share Price Forecast, Short-Term "RXRX" Stock Prediction for Next Days and Weeks Walletinvestor.com Recursion Pharmaceuticals Inc (RXRX) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 NVIDIA Corporation Common Stock. $416.10 +5.93 +1.45%. ARM. Arm Holdings plc American Depositary Shares. $51.32 -0.84 -1.61%. Find the latest analyst research for Recursion Pharmaceuticals, Inc ...JPMorgan Trims Price Target on Recursion Pharmaceuticals to $10 From $11, Maintains Neutral Rating. Nov. 13. MT. Needham Adjusts Recursion Pharmaceuticals Price Target to $15 From $17, Maintains Buy Rating. Nov. 10. MT. Recursion Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September …Find the latest Baudax Bio, Inc. (BXRX) stock quote, history, news and other vital information to help you with your stock trading and investing.As of Monday, July 24, Recursion Pharmaceuticals Inc’s RXRX share price has dipped by 7.69%, which has investors questioning if this is right time to buy. Premium ... Whether you decide it’s a good time to buy or sell Recursion Pharmaceuticals Inc’s stock based on its stock price forecast is ultimately up to you.
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...Nov 22, 2023 · The company's shares are currently changing hands for $7.07 apiece, but the consensus one-year target for the stock is $15.57, which implies that it could rise by about 120% over the next 12 months. For RXRX stock, which has suffered sharp losses against a long-term framework, AI may put the underlying company on the right track again. Still, investors need to be aware of separating the ...RXRX Stock Rips on Nvidia Investment. Shares of RXRX rallied more than 75% on Wednesday, July 12. At one point, the stock traded as high as $14.99, up 121% on the day.30 сент. 2023 г. ... NASDAQ: RXRX. Recursion Pharmaceuticals. Recursion Pharmaceuticals Stock Quote. Market Cap. $2B. Today's Change. (0.43%) $0.03. Current Price.The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...View the latest Recursion Pharmaceuticals Inc. (RXRX) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Follow your favorite stocks CREATE FREE ACCOUNT Over the next 10 years, AI could increase productivity by 1.5 percent per year. And that could increase S&P500 profits by 30 percent or more over ...Get free stock tools, free stock ratings, free stock charts and calculate the value of stocks to buy
We’ve all flipped between different weather apps, wondering why each is giving a slightly different report. Before we look at AccuWeather, it’s important to understand the basics of weather forecasting. In the past, weather predictions were...Recursion Pharmaceuticals uses AI and experimental biology to discover new treatments for diseases. Check out why I'm bullish on RXRX stock.Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Get the latest Recursion Pharmaceuticals, Inc RXRX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Earnings for Recursion Pharmaceuticals are expected to decrease in the coming year, from ($1.67) to ($1.91) per share. Recursion Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 26th, 2024 based off prior year's report dates. Read More.Now's a great time to invest in biotechs that have AI as a tailwind. Ginkgo Bioworks uses AI to run bioengineering projects for other biotechs. Recursion Pharmaceuticals uses AI to find good leads ...
Schrödinger (SDGR 3.92%) and Recursion Pharmaceuticals (RXRX 6.64%) are both biotechs that want to use AI to streamline the drug discovery and development process. And that makes them hot stocks ...
beststocks.com
Sep 22, 2023 · According to data from CNN Money, the company had 7 analysts offering 12-month price forecasts. The median target price was $14.00, with a high estimate of $35.00 and a low estimate of $9.00. The consensus among the 7 polled investment analysts was to hold the stock of Recursion Pharmaceuticals Inc. This rating had remained steady since ... Sep 11, 2023 · Recursion Pharmaceuticals (RXRX 7.88%) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ... Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Find the latest Recursion Pharmaceuticals, Inc. RXRX analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...About the Recursion Pharmaceuticals, Inc. Class A Common Stock stock forecast. As of 2023 December 02, Saturday current price of RXRX stock is 6.910$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Recursion Pharmaceuticals stock price has been showing a declining tendency so we …Nov 30, 2023 · Analyst Forecast According to 6 analysts, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $15.33, which is an increase of 107.44% from the latest price. Insiders have purchased a total of 581,017 RXRX shares in the last 24 months for a total of $4,440,853.30 bought. Which Recursion Pharmaceuticals insiders have been selling company stock? The following insiders have sold RXRX shares in the last 24 months: Blake Borgeson ($2,846,394.44), Christopher Gibson ($14,439,192.59), …The exchange reported a loss of $2.43 per share, compared to forecasts of a $2.52 loss per share, according to the FactSet consensus. Revenue plummeted 75% to $629.1 million, but still beat ...The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...Recursion Pharmaceuticals Inc. research and ratings by Barron's. View RXRX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns.
Recursion Pharmaceuticals Inc Cl A (RXRX) $7.05 0.38 (5.70%) 16:00 EST RXRX Stock Quote Delayed 30 Minutes.Zillow is worth $8.3 billion right now, so if it reaches its 2025 sales estimate and continues to grow thereafter, it should breeze past a $10 billion valuation by 2030. 2. Duolingo: Potential ...Zolak. Clinical-stage biotech Recursion Pharmaceuticals ( NASDAQ: RXRX) added ~7% in the pre-market Monday after announcing agreements to acquire Cyclica and Valence, two Canadian companies ...Instagram:https://instagram. xbil etfapple stock.forecastwhere can i short sell stocksbest stock for day trade Recursion Pharmaceuticals, Inc. (RXRX) share price prediction for 2023, 2024, 2025, 2026 and 2027. RXRX one year forecast. Recursion Pharmaceuticals stock monthly and ... what is the fastest audilqd ticker According to the issued ratings of 2 analysts in the last year, the consensus rating for Xerox stock is Sell based on the current 2 sell ratings for XRX. The average twelve-month price prediction for Xerox is $14.67 with a high price target of $17.00 and a low price target of $12.00. Learn more on XRX's analyst rating history.4.31%. €8.59M. RXRX | Complete Recursion Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. benzinga pro insider report Recursion Pharma may be a biotech stock, but it scored a $50 million investment from Nvidia to fund its AI technology in mid-July - making NVDA a significant stakeholder in RXRX.Should You Buy or Sell Recursion Pharmaceuticals Stock? Get The Latest RXRX Stock Analysis, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.The company raised guidance for annual organic revenue growth from an earlier forecast of between 5% and 7% to between 6% and 8%. It also raised annual adjusted EPS to be between $3.70 and $3.85 ...